McNeil Consumer & Specialty Pharmaceuticals Inc. Sustainability Profile
McNeil Consumer & Specialty Pharmaceuticals Inc., a subsidiary of Johnson & Johnson, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 1959, the company has established itself as a leader in over-the-counter (OTC) medications, focusing on pain relief, allergy, and gastrointestinal health. With a diverse portfolio that includes well-known brands such as Tylenol, Motrin, and Benadryl, McNeil is recognised for its commitment to quality and consumer trust. The company operates primarily in North America, with significant influence in global markets. Notable achievements include the development of innovative formulations and a strong emphasis on safety and efficacy, positioning McNeil as a trusted name in consumer healthcare. Through its dedication to research and development, McNeil continues to meet the evolving needs of consumers, solidifying its market position in the competitive pharmaceutical landscape.
DitchCarbon Score
How does McNeil Consumer & Specialty Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
McNeil Consumer & Specialty Pharmaceuticals Inc.'s score of 51 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
McNeil Consumer & Specialty Pharmaceuticals Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Kenvue Inc., which may influence its climate commitments and emissions reporting. As of now, McNeil has not publicly outlined any specific reduction targets or initiatives related to carbon emissions. The absence of documented reduction targets suggests that the company may be in the early stages of developing a comprehensive climate strategy. Given its affiliation with Kenvue Inc., any potential climate commitments or emissions data may be cascaded from this parent organisation. Kenvue Inc. is expected to have its own sustainability initiatives and targets, which could indirectly impact McNeil's approach to carbon emissions and climate action. In summary, while McNeil Consumer & Specialty Pharmaceuticals Inc. does not currently report specific emissions data or reduction targets, its relationship with Kenvue Inc. may play a significant role in shaping its future climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 73,841,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 136,832,000 | 000,000,000 | 000,000,000 | - | - |
| Scope 3 | 3,652,178,000 | 0,000,000,000 | 0,000,000,000 | - | - |
How Carbon Intensive is McNeil Consumer & Specialty Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is McNeil Consumer & Specialty Pharmaceuticals Inc.'s Location?
McNeil Consumer & Specialty Pharmaceuticals Inc.'s Scope 3 Categories Breakdown
McNeil Consumer & Specialty Pharmaceuticals Inc.'s Scope 3 emissions, which decreased by 19% last year and decreased by approximately 24% since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 76% of Scope 3 emissions.
Top Scope 3 Categories
McNeil Consumer & Specialty Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
McNeil Consumer & Specialty Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
